Irvine, California-based Axonics tabbed Kari Keese, VP of finance and accounting, to succeed Dearen. Her appointment goes into effect on Oct. 2.
“On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-founder and longtime colleague, for his many contributions to the company over the last 10 years,” said CEO Raymond W. Cohen.
Cohen added that Dearen “played an instrumental role” in the company’s success and the value created for its shareholders.
“It has been a privilege working alongside the talented, mission-driven team at Axonics,” Dearen added. “I am incredibly proud of the impact the company’s therapies have had on improving the quality of life for tens of thousands of incontinence patients. I will follow Axonics with pride as it continues on its path to market leadership.”
Keese, having joined Axonics in 2014, leads the company’s finance and accounting functions. She previously served as director of finance and controller.
Before Axonics, Keese held the position of controller at Vessix Vascular, a company previously led by Cohen and Dearen. Boston Scientific acquired Vessix Vascular in 2012.
“Kari has been with Axonics for over nine years and has served as a valuable member of our senior management team,” Cohen said. “She is a seasoned executive and we are confident that she will excel as our next chief financial officer. Kari’s deep knowledge of the company and track record of financial leadership make her an ideal successor to Dan.”
Axonics also reaffirmed its fiscal year 2023 revenue guidance of $358 million that it provided on July 27.
